CSIMarket Company Name, Ticker, Industry, else..
 
Elicio Therapeutics Inc   (NASDAQ: ELTX)
 
Price: $1.9100 $0.02 1.058%
Day's High: $2.0199999809265137 Week Perf: -4.02 %
Day's Low: $ 1.91 30 Day Perf: -37.89 %
Volume (M): 482,493 52 Wk High: $ 16.00
Volume (M$): $ 0 52 Wk Avg: $8.10
Open: $1.92 52 Wk Low: $1.71



 Market Capitalization (Millions $) 37
 Shares Outstanding (Millions) 19
 Employees 33
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -38
 Cash Flow (TTM) (Millions $) -7
 Capital Exp. (TTM) (Millions $) 0

Business Description


Elicio Therapeutics Inc is a biotechnology company that specializes in the development of immunotherapies for cancer and other diseases. The company utilizes its proprietary Amphiphile Immune Modulating (AIM) technology platform to enhance the effectiveness of immune responses and enable targeted delivery of therapies to specific cells. Their approach is aimed at activating and amplifying the body's immune system to fight and eradicate cancer cells. Elicio Therapeutics is committed to leveraging the potential of immunotherapy to improve patient outcomes and transform the treatment landscape for various diseases.


   Company Address: 451 D Street, 5th Floor Boston 2210 MA
   Company Phone Number: 209-0050   Stock Exchange / Ticker: NASDAQ ELTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -2.31%    
JNJ        1.18% 
LLY        2.34% 
MRK        3.21% 
PFE        0.07% 
REGN        0.56% 
• View Complete Report
   



Clinical Study

Advancing Immunotherapy Frontiers Elicio Therapeutics Promising Progress in Targeting mKRAS Mutations

Published Fri, Nov 7 2025 3:31 PM UTC

: This article delves into the recent developments and promising advancements announced by Elicio Therapeutics, a clinical-stage biotechnology leader in cancer immunotherapy. By examining the emerging data from their ongoing Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical data on ELI-004, we assess their impact on pancreatic ductal adenocarcinoma (PDAC) treatment an...
Shares

Blending Financial Acumen with Talent Strategy: Elicio Therapeutics Accelerates Cancer Treatment Innovations With $10M Market Offering and Key Staff Inducements,

Published Thu, Jan 30 2025 1:01 PM UTC

Elicio Therapeutics Solidifies Financial Footing with $10 Million Registered Direct Offering and Strategic Talent Acquisition BOSTON, Jan. 30, 2025 Elicio Therapeutics, Inc. (Nasdaq: ELTX), a pioneering clinical-stage biotechnology firm devoted to developing state-of-the-art immunotherapies for cancer treatment, has recently announced a promising $10.0 million registered ...
Clinical Study

Elicio Therapeutics Navigating Clinical Success and Competitive Financial Challenges with ELI-002s Promising Phase 1...

Published Thu, Dec 12 2024 12:00 PM UTC

Elicio Therapeutics Promising Outlook Amidst Competitive Financial Landscape: A Look at the ELI-002 Phase 1 AMPLIFY-201 Study Results Elicio Therapeutics, a company at the forefront of innovation in cancer treatment, recently showcased its advancements at the ESMO Immuno-Oncology Congress 2024. The company presented updated results from its ELI-002 Phase 1 AMPLIFY-201 study...
Clinical Study

At the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting, Elicio Therapeuti...

Published Thu, Nov 7 2024 9:05 PM UTC

Targeted Immunotherapy Progress: Elicio Therapeutics ELI-002 Demonstrates Promising Results in Combating KRAS Mutations At the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting, Elicio Therapeutics shared compelling translational data from the Phase 1 AMPLIFY-7P study of their investigational agent, ELI-002. Initial findings from this ongoing study indicate th...
Stock Market Announcement

Elicio Therapeutics Integrates Talent Acquisition and Shareholder Value Amidst Rising Market Fortunes,

Published Wed, Oct 16 2024 12:31 PM UTC

Harnessing Talent: Elicio Therapeutics Strategic Use of Inducement Stock Options Amidst a Surge in Market ValuationIn the dynamic landscape of biotechnology, attracting and retaining top talent is paramount for innovation and progress. Enter Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotech firm headquartered in Boston, which is making strategic moves to bo...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 4.63
PEG (TTM) -

Financial Strength Current
Quick Ratio 2.55
Working Capital Ratio 2.84
Leverage Ratio (MRQ) 2.95
Total Debt to Equity 1.2
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -2.18 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 1.22 $
Book Value 0.41 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,146,697
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.